The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Wedbush Assumes Coverage of Voyager With Outperform Rating
Wednesday Ends With Index Decline | Wall Street Today
FDA Investigating Safety Risks of Bluebird's Skysona
Wolfe's Short Ideas: Companies With Potential Dividend Cuts
Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5